Jeffrey Tan

Summary

Publications

  1. pmc Expenditure and resource utilisation for cervical screening in Australia
    Jie Bin Lew
    Cancer Research Division, Cancer Council NSW, 153 Dowling Street, Woolloomooloo, Sydney, NSW 2011, Australia
    BMC Health Serv Res 12:446. 2012
  2. doi request reprint Hybrid Capture II testing for high-risk human papillomavirus DNA in the follow-up of women treated for high-grade cervical intraepithelial neoplasia
    Jeffrey H J Tan
    Department of Obstetrics and Gynaecology, University of Melbourne, Melbourne, Australia
    J Low Genit Tract Dis 17:308-14. 2013
  3. doi request reprint The attitudes of Australian gynaecologists to HPV vaccination: an ASCCP survey
    Jeffrey Tan
    Oncology and Dysplasia Unit, The Royal Women s Hospital, Parkville, Victoria, Australia
    Aust N Z J Obstet Gynaecol 50:472-7. 2010
  4. doi request reprint New technologies and advances in colposcopic assessment
    Jeffrey H J Tan
    Oncology and Dysplasia Unit, Royal Women s Hospital, Parkville, Victoria, Australia
    Best Pract Res Clin Obstet Gynaecol 25:667-77. 2011
  5. doi request reprint Clearance of human papillomavirus in women treated for cervical dysplasia
    Elya E Moore
    Department of Microbiology and Infectious Diseases, Royal Women s Hospital, Parkville, Victoria, Australia
    Obstet Gynecol 117:101-8. 2011
  6. ncbi request reprint Should the Pap smear be repeated at the first colposcopy visit?
    Grace Dolman
    The University Department of Obstetrics and Gynaecology and Oncology Dysplasia Unit, Royal Women s Hospital, Melbourne, Australia
    Aust N Z J Obstet Gynaecol 45:514-7. 2005
  7. pmc Measuring effectiveness of the cervical cancer vaccine in an Australian setting (the VACCINE study)
    Elisa J Young
    Department of Microbiology and Infectious Diseases, Royal Women s Hospital, Parkville, Melbourne, VIC 3052, Australia
    BMC Cancer 13:296. 2013
  8. pmc Comparison of the Digene Hybrid Capture 2 assay and Roche AMPLICOR and LINEAR ARRAY human papillomavirus (HPV) tests in detecting high-risk HPV genotypes in specimens from women with previous abnormal Pap smear results
    Matthew P Stevens
    Department of Microbiology, The Royal Women s Hospital, 132 Grattan Street, Carlton, Victoria 3053, Australia
    J Clin Microbiol 45:2130-7. 2007
  9. doi request reprint Outcome in women with no endocervical component on cervical cytology after treatment for high-grade cervical dysplasia
    Alice Huang
    Department of Oncology and Dysplasia, Royal Women s Hospital, Parkville, Victoria, Australia
    Aust N Z J Obstet Gynaecol 49:426-8. 2009
  10. doi request reprint Clinicians' attitude towards changes in Australian National Cervical Screening Program
    Desiree Yap
    Dysplasia Unit, Royal Women s Hospital, Parkville, Victoria, Australia Electronic address
    J Clin Virol 76:S81-7. 2016

Collaborators

Detail Information

Publications12

  1. pmc Expenditure and resource utilisation for cervical screening in Australia
    Jie Bin Lew
    Cancer Research Division, Cancer Council NSW, 153 Dowling Street, Woolloomooloo, Sydney, NSW 2011, Australia
    BMC Health Serv Res 12:446. 2012
    ..This study aimed to provide a baseline for such a review by quantifying screening program resource utilisation and costs in 2010...
  2. doi request reprint Hybrid Capture II testing for high-risk human papillomavirus DNA in the follow-up of women treated for high-grade cervical intraepithelial neoplasia
    Jeffrey H J Tan
    Department of Obstetrics and Gynaecology, University of Melbourne, Melbourne, Australia
    J Low Genit Tract Dis 17:308-14. 2013
    ....
  3. doi request reprint The attitudes of Australian gynaecologists to HPV vaccination: an ASCCP survey
    Jeffrey Tan
    Oncology and Dysplasia Unit, The Royal Women s Hospital, Parkville, Victoria, Australia
    Aust N Z J Obstet Gynaecol 50:472-7. 2010
    ..With human papilloma virus (HPV) vaccines now approved for women up to 45 years of age, gynaecologists in Australia will be approached increasingly for advice on whether to have the HPV vaccine...
  4. doi request reprint New technologies and advances in colposcopic assessment
    Jeffrey H J Tan
    Oncology and Dysplasia Unit, Royal Women s Hospital, Parkville, Victoria, Australia
    Best Pract Res Clin Obstet Gynaecol 25:667-77. 2011
    ..Opportunities remain for global collaboration in research, education and training to promote more effective and affordable cervical screening, and to enhance the skills of colposcopists worldwide...
  5. doi request reprint Clearance of human papillomavirus in women treated for cervical dysplasia
    Elya E Moore
    Department of Microbiology and Infectious Diseases, Royal Women s Hospital, Parkville, Victoria, Australia
    Obstet Gynecol 117:101-8. 2011
    ..To estimate human papillomavirus (HPV) clearance of women with cervical abnormalities after treatment...
  6. ncbi request reprint Should the Pap smear be repeated at the first colposcopy visit?
    Grace Dolman
    The University Department of Obstetrics and Gynaecology and Oncology Dysplasia Unit, Royal Women s Hospital, Melbourne, Australia
    Aust N Z J Obstet Gynaecol 45:514-7. 2005
    ..To determine whether there is any benefit in repeating the Pap smear at the time of colposcopy in women referred to a teaching hospital dysplasia clinic...
  7. pmc Measuring effectiveness of the cervical cancer vaccine in an Australian setting (the VACCINE study)
    Elisa J Young
    Department of Microbiology and Infectious Diseases, Royal Women s Hospital, Parkville, Melbourne, VIC 3052, Australia
    BMC Cancer 13:296. 2013
    ..In sub study B, the distribution of human papillomavirus genotypes detected in high grade cervical intraepithelial neoplastic lesions from vaccine eligible women is being assessed...
  8. pmc Comparison of the Digene Hybrid Capture 2 assay and Roche AMPLICOR and LINEAR ARRAY human papillomavirus (HPV) tests in detecting high-risk HPV genotypes in specimens from women with previous abnormal Pap smear results
    Matthew P Stevens
    Department of Microbiology, The Royal Women s Hospital, 132 Grattan Street, Carlton, Victoria 3053, Australia
    J Clin Microbiol 45:2130-7. 2007
    ..Both PCR-based HPV tests may be valuable in the management of care for women with underlying cervical abnormalities, in predicting treatment success, and in studying the clearance or acquisition of new infections...
  9. doi request reprint Outcome in women with no endocervical component on cervical cytology after treatment for high-grade cervical dysplasia
    Alice Huang
    Department of Oncology and Dysplasia, Royal Women s Hospital, Parkville, Victoria, Australia
    Aust N Z J Obstet Gynaecol 49:426-8. 2009
    ..This study aims to determine if the lack of an endocervical component in women with previously treated high-grade abnormalities of the cervix increases the risk of subsequent cytological abnormalities...
  10. doi request reprint Clinicians' attitude towards changes in Australian National Cervical Screening Program
    Desiree Yap
    Dysplasia Unit, Royal Women s Hospital, Parkville, Victoria, Australia Electronic address
    J Clin Virol 76:S81-7. 2016
    ..Australian guidelines for cervical cancer screening are being revised under the "renewal program". Physicians' willingness to accept these changes will play a pivotal role in its success...
  11. ncbi request reprint Women with low-grade abnormalities on Pap smear should be referred for colposcopy
    Amanda Fairman
    University Department of Obstetrics and Gynaecology, Melbourne, Victoria, Australia
    Aust N Z J Obstet Gynaecol 44:252-5. 2004
    ..To assess cytological, colposcopic and histological outcomes in women referred to a teaching hospital dysplasia clinic with low-grade changes on screening Pap smear...
  12. ncbi request reprint Confocal endomicroscopy: a novel imaging technique for in vivo histology of cervical intraepithelial neoplasia
    Jeffrey Tan
    Royal Women s Hospital, Carlton, Victoria, Australia
    Expert Rev Med Devices 4:863-71. 2007
    ....